ZACKS RESEARCH

FUNDS

PORTFOLIO

BROKER RESEARCH

MARKETS

SCREENING

EDUCATION

SERVICES

Earnings

EPS Surprises

Mutual Funds

Options

My Account

Help

What's Up With These Ridiculous Stock Gains?

Steve Reitmeister didn't want me to tell you this. He felt that one strategy's performance stands out so much that... Read on >>

Quote:

Search for Ticker

Free Membership

Search:

ACHN: Achillion Pharmaceuticals Inc - Full Company Report Enter Ticker:

Quote	Estimates	Charts	Company Reports	News	Financials

Full Company Report \| Estimates \| Brokerage Recommendations \| Comparison to Industry \| Insiders \| Brokerage Reports \| Zacks Equity Research \| Annual Report

ACHILLION PHARMACEUTICALS INC (NASD)
ACHN	1.88	N/A	(N/A%)	Vol. 1,900	15:59 ET

ACHILLION PHARMACEUTICALS, INC. is an innovative pharmaceutical company dedicated to bringing important new treatments to patients with infectious disease. The company's proven discovery and development teams have advanced multiple product candidates with novel mechanisms of action. Achillion is focused on solutions for the most challenging problems in infectious disease -- HIV, hepatitis and resistant bacterial infections. Achillion sees significant competitive advantages in developing anti-infective drugs compared to developing drugs in other therapeutic areas. The emergence of drug resistance seen with current antiviral and antibacterial therapies creates a continuing need for new drugs, providing a large and growing potential business opportunity. In addition, development cycle times tend to be somewhat shorter in infectious disease than other therapeutic areas, and early drug development results tend to be more predictive of longer term results.

General Information

ACHILLION PHARM

- -, - - Phone: - Fax: - Web: - Email: None

Industry	MED-BIOMED/GENE
Sector:	Medical

Fiscal Year End	December
Last Reported Quarter	09/30/09
Next EPS Date	03/24/2010

Price and Volume Information

Zacks Rank
Yesterday's Close	1.88
52 Week High	2.42
52 Week Low	0.65
Beta	-0.28
20 Day Moving Average	33,936.75
Target Price Consensus	3.17

% Price Change
4 Week	-3.57
12 Week	8.69
YTD	176.51

% Price Change Relative to S&P 500
4 Week	-7.26
12 Week	-1.89
YTD	133.68

Share Information
Shares Outstanding (millions)	26.66
Market Capitalization (millions)	50.12
Short Ratio	1.42
Last Split Date	N/A

Dividend Information
Dividend Yield	0.00%
Annual Dividend	$0.00
Payout Ratio	0.00
Change in Payout Ratio	0.00
Last Dividend Payout / Amount	NA / $0.00

EPS Information
Current Quarter EPS Consensus Estimate	-0.21
Current Year EPS Consensus Estimate	-0.93
Estimated Long-Term EPS Growth Rate	-
Next EPS Report Date	03/24/2010

Consensus Recommendations
Current (1=Strong Buy, 5=Strong Sell)	2.33
30 Days Ago	2.33
60 Days Ago	2.00
90 Days Ago	1.80

Fundamental Ratios

P/E
Current FY Estimate:	-
Trailing 12 Months:	-
PEG Ratio	-

EPS Growth
vs. Previous Year	25.81%
vs. Previous Quarter	0.00%

Sales Growth
vs. Previous Year	-97.22%
vs. Previous Quarter:	-93.72%

Price Ratios
Price/Book	3.78
Price/Cash Flow	-
Price / Sales	-

ROE
09/30/09	-145.48
06/30/09	-125.25
03/31/09	-132.98

ROA
09/30/09	-90.12
06/30/09	-81.21
03/31/09	-82.04

Current Ratio
09/30/09	-
06/30/09	-
03/31/09	3.22

Quick Ratio
09/30/09	-
06/30/09	-
03/31/09	3.22

Operating Margin
09/30/09	-
06/30/09	-
03/31/09	-

Net Margin
09/30/09	-
06/30/09	1,815.91
03/31/09	2,514.73

Pre-Tax Margin
09/30/09	-
06/30/09	1,815.91
03/31/09	2,514.73

Book Value
09/30/09	-
06/30/09	0.50
03/31/09	0.71

Inventory Turnover
09/30/09	-
06/30/09	-
03/31/09	-

Debt-to-Equity
09/30/09	-
06/30/09	-
03/31/09	0.00

Debt to Capital
09/30/09	-
06/30/09	-
03/31/09	0.00


About Zacks \| Advertise \| Media \| Careers \| Contact Us \| Help Disclaimer \| Privacy Policy \| Sitemap NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed. Copyright 2009 Zacks Investment Research